Iuvo
Iuvo is a U.S.-based, ophthalmology-focused contract research organization that provides end-to-end clinical trial services — from preclinical through regulatory submission — exclusively to pharmaceutical, biotechnology, and medical device companies developing eye care therapies.
- Company typePrivate
- Founded2015
- HeadquartersRush, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Iuvo does
iuvo is a U.S.-based, private contract research organization (CRO) founded in 2015 that operates exclusively in the ophthalmology therapeutic area. The company provides end-to-end clinical research services to pharmaceutical companies, biotechnology firms, and medical device companies developing ophthalmic therapies, spanning anterior and posterior segment indications, novel retinal therapies, gene and cell therapies, and complex ocular device trials. iuvo positions itself as a 100% ophthalmology-only CRO, distinguishing itself from generalist CROs through deep domain specialization, and claims involvement in 10 of the 23 FDA-approved ophthalmic drugs since 2008.
The company's core offering is professional services — full-service clinical trial execution from protocol development through regulatory submission — delivered through an enterprise field sales motion targeting drug and device innovators. Its underlying capability stack combines decades of specialized ophthalmic clinical research experience with a global site and investigator network that enables trial management across North America and internationally. The technology layer is human-expertise-led rather than software-platform-led: no proprietary AI/ML systems, data products, or software platforms are described in available sources.
In January 2024, iuvo BioScience acquired Promedica International, a California-based ophthalmology-focused clinical CRO, extending its service surface from clinical-only to a combined preclinical-through-clinical platform and adding a West Coast U.S. presence alongside its East Coast headquarters in Rush. Following the acquisition, Shannon Stoddard was appointed President of Clinical Research to lead the combined organization's operations. Revenue mechanics are project-based professional services engagements with negotiated, quote-driven pricing; no public pricing, revenue figures, or funding rounds are disclosed.
Iuvo firmographics
Firmographics- Name
- Iuvo
- Legal name
- Iuvo
- Website
- https://iuvobioscience.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Iuvo is a U.S.-based, ophthalmology-focused contract research organization that provides end-to-end clinical trial services — from preclinical through regulatory submission — exclusively to pharmaceutical, biotechnology, and medical device companies developing eye care therapies.
- Ownership category
- akta.pro rank
Iuvo industry classification
Industry- Product category
- Ophthalmology Contract Research Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where Iuvo is headquartered
LocationHeadquarters
- HQ city
- Rush
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Iuvo business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Clinical Research Services: Full-service contract research organization providing preclinical and clinical development services exclusively for ophthalmology. Revenue generated through project-based professional service engagements with pharmaceutical, biotech, and medical device clients.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Iuvo product offering
Product offeringCore offering
iuvo is a full-service contract research organization (CRO) that provides preclinical and clinical research services exclusively for ophthalmology. It manages end-to-end trial execution for pharmaceutical, biotechnology, and medical device companies developing eye care therapies, spanning protocol development through regulatory submission across anterior and posterior segments.
Product overview
Iuvo is a full-service ophthalmology-focused contract research organization (CRO) providing end-to-end clinical research services from concept to commercialization. The company specializes exclusively in ophthalmology, supporting all stages of clinical trials including early-phase through pivotal studies. Following the January 2024 acquisition of Promedica International, the combined organization expanded its capabilities to provide comprehensive ophthalmic clinical research services with global reach across North America and internationally.
Differentiator
Problem solved
Functional benefit
Products and services
- Ophthalmic Clinical Research Services
Quantifiable outcome
- Supported 10 of 23 FDA-approved ophthalmic drugs since 2008
- +1 more outcomes
Companies that use Iuvo
Customer profileSegments3 records
Ideal customer profiles3 records
Iuvo technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Iuvo partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Promedica Internationalcoreiuvo BioScience acquired Promedica International, a California-based ophthalmology-focused clinical CRO, in January 2024. The acquisition aimed to enhance capabilities in ophthalmic clinical research, expand the combined organization's service offerings, and support all stages of ophthalmic clinical research. Following the acquisition, Shannon Stoddard was appointed President of Clinical Research. This strategic combination created an end-to-end ophthalmology research platform spanning preclinical through clinical development stages.
Scale indicators3 records
Recent moves4 records
Expansion highlights5 records
Iuvo competitors and assessment
Company assessmentBroad incumbents
- ICON plc: ICON is one of the largest global CROs, offering comprehensive clinical research services across all major therapeutic areas including ophthalmology. It competes with iuvo for large, multi-region ophthalmology trials.
- IQVIA: IQVIA is the world's largest CRO with extensive ophthalmology capabilities. It competes with iuvo on global trials, real-world evidence, and large sponsor preferred-vendor relationships.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-to-large global CRO with ophthalmology among its therapeutic specialties. While broader in scope than iuvo, it competes for ophthalmic trial work and has established global delivery infrastructure iuvo lacks.
- Charles River Laboratories: Charles River is a large preclinical and clinical CRO with ophthalmology research models and services. It overlaps with iuvo's preclinical capability and competes for early-stage ophthalmology work.
- Syneos Health: Syneos Health is a major global CRO with broad therapeutic area coverage including ophthalmology. As a large incumbent, it competes with iuvo for ophthalmic trial engagements from large pharma sponsors.
- Medpace: Medpace is a publicly-traded global CRO with full-service clinical development across many therapeutic areas including ophthalmology. It represents a scaled incumbent that iuvo competes against for mid-to-large ophthalmology programs.
Emerging players
- Caidya: Caidya (formed from the Clinipace Worldwide and dMed merger) is a mid-sized global CRO with therapeutic breadth including ophthalmology. It represents a peer in the mid-tier CRO space competing for similar-sized ophthalmology programs.
Direct peers
- Ora Inc: Ora is the leading ophthalmology-focused CRO, offering preclinical and clinical services for ocular therapeutics. It is iuvo's closest direct competitor in the ophthalmology CRO niche, targeting the same pharmaceutical, biotech, and medical device sponsors.
- Lexitas Pharma Services: Lexitas is a dedicated ophthalmology CRO providing clinical trial services for eye care therapies. It competes with iuvo for ophthalmic drug and device trials, with comparable therapeutic-area specialization.
- Pharm-Olam: Pharm-Olam is a mid-sized CRO with a meaningful ophthalmology therapeutic area focus. It offers similar full-service clinical research capabilities for sponsors developing ocular therapies and competes for the same customer segments as iuvo.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Iuvo social profiles
Digital presenceIuvo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Iuvo leadership team
Management profileNumber of profiles
Profiles2 records
Iuvo subsidiaries and ownership
Company hierarchySubsidiaries1 record
Iuvo funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Iuvo M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Iuvo
What does Iuvo do?
iuvo is a full-service contract research organization (CRO) that provides preclinical and clinical research services exclusively for ophthalmology. It manages end-to-end trial execution for pharmaceutical, biotechnology, and medical device companies developing eye care therapies, spanning protocol development through regulatory submission across anterior and posterior segments.
Is Iuvo a public or private company?
Iuvo is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Iuvo founded?
Iuvo was founded in 2015. It employs 51 to 100 people.
Where is Iuvo based?
Iuvo is headquartered in Rush, United States, in the North America region.
How does Iuvo make money?
One revenue line is on record: clinical Research Services.
Who are Iuvo's main competitors?
Broad incumbents on record are ICON plc, IQVIA, Worldwide Clinical Trials, Charles River Laboratories, Syneos Health and Medpace. Caidya is listed as an emerging player. Direct peers are Ora Inc, Lexitas Pharma Services and Pharm-Olam.
Does Iuvo have an API?
No public API is recorded for Iuvo.
What industry is Iuvo in?
Iuvo's product category is Ophthalmology Contract Research Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.